Celgene, Evotec's partner Exscientia and Evotec began a three-year AI drug discovery collaboration in oncology and autoimmunity.

Exscientia applies its full-stack AI drug discovery capabilities to run each project from gene to drug candidate. Terms include $25 million upfront, milestones and tiered royalties. The page names no candidates.

Evotec is a drug discovery and development services company that pairs AI partners with its integrated R&D platform in oncology and immunology.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.